Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.30 |
| ▸ | IKBKB | O14920 | 1/20 | 0.30 |
| ▸ | CHUK | O15111 | 1/20 | 0.30 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.30 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.30 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.30 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18965753 | 0.72 | TDP1 (0.38) | MAPK1IKBKBCHUK | |
| SCHEMBL1698033 | 0.71 | ALDH1A1 (0.33) | PDK1NOS1 | |
| SCHEMBL14536777 | 0.71 | CYP2A6 (0.32) | POLB | |
| SCHEMBL17452503 | 0.71 | ALOX5 (0.32) | — | |
| SCHEMBL8343981 | 0.71 | IKBKB (0.34) | IKBKBCHUKNOS1 | |
| SCHEMBL17339874 | 0.71 | CCNB2 (0.34) | IKBKBCHUKNOS1 | |
| SCHEMBL14817516 | 0.67 | CCR1 (0.45) | MAPK1POLBFGFR1CSNK2A2CSNK2B | |
| SCHEMBL1697858 | 0.67 | CYP2A6 (0.34) | — | |
| SCHEMBL1697879 | 0.67 | CYP2A6 (0.32) | — | |
| SCHEMBL12434 | 0.67 | CYP2A6 (0.55) | PDK1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11524966-B1 | Carboxamides as ubiquitin-specific protease inhibitors | VALO HEALTH, INC. (US) | 2022-12-13 | — | — | US | claimed |
| EP-4219465-A2 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme Inc (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-3498701-B1 | PRMT5 INHIBITORS AND USES THEREOF | EPIZYME INC (US) | 2023-02-22 | — | — | EP | disclosed |
| US-10865216-B2 | Tricyclic Gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-12-15 | — | — | US | disclosed |
| EP-2935247-B1 | PRMT5 INHIBITORS AND USES THEREOF | EPIZYME INC (US) | 2019-08-28 | — | — | EP | disclosed |
| EP-3498701-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme Inc (US) | 2019-06-19 | — | — | EP | disclosed |
| EP-3154973-B1 | TRICYCLIC COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2018-03-21 | — | — | EP | disclosed |
| EP-2935243-B1 | PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF | EPIZYME INC (US) | 2018-03-14 | — | — | EP | disclosed |
| US-9902702-B2 | Spirocycloheptanes as inhibitors of rock | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-02-27 | — | — | US | disclosed |
| US-9846160-B2 | Ganglioside GD2 as a marker and target on cancer stem cells | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMS (US) | 2017-12-19 | — | — | US | disclosed |
| US-20100331317-A1 | BENZODIAZEPINE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-12-30 | — | — | US | disclosed |
| WO-2010137738-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-12-02 | — | — | WO | disclosed |
| EP-2155739-B1 | 2-CYCLOPROPYL-THIAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-10-06 | — | — | EP | disclosed |
| US-20100222328-A1 | 2-CYCLOPROPYL-THIAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-09-02 | — | — | US | disclosed |
| US-20100222328-A1 | 2-CYCLOPROPYL-THIAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-09-02 | — | — | US | disclosed |
| US-20100016292-A1 | INHIBITORS OF LETHAL FACTOR PROTEASE | THE BURNHAM INSTITUTE (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100016292-A1 | INHIBITORS OF LETHAL FACTOR PROTEASE | THE BURNHAM INSTITUTE (US) | 2010-01-21 | — | — | US | disclosed |
| WO-2008139416-A1 | 2-CYCLOPROPYL-THIAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-11-20 | — | — | WO | disclosed |
| US-20070203209-A1 | Useful indole compounds | IRONWOOD PHARMACEUTICALS, INC. | 2007-08-30 | — | — | US | disclosed |
| WO-2007022501-A2 | USEFUL INDOLE COMPOUNDS | MICROBIA, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524966-B1 | Carboxamides as ubiquitin-specific protease inhibitors | USP28, USP25, USP24 | PDK1 1571/4885MAPK1 2061/4885POLB 3179/4885 |
| US-20100222328-A1 | 2-CYCLOPROPYL-THIAZOLE DERIVATIVES | HCRTR2, HCRTR1, NPY2R | PDK1 2038/4885MAPK1 2856/4885POLB 4821/4885 |
| US-20100016292-A1 | INHIBITORS OF LETHAL FACTOR PROTEASE | APAF1, F11, SERPINB1 | PDK1 4635/4885MAPK1 2525/4885POLB 3712/4885 |
| US-20070203209-A1 | Useful indole compounds | TPH2, HRH2, HRH1 | PDK1 3375/4885MAPK1 4072/4885POLB 4710/4885 |
| US-20100331317-A1 | BENZODIAZEPINE COMPOUND AND PHARMACEUTICAL COMPOSITION | KCNA5, KCNA1, KCNAB1 | PDK1 916/4885MAPK1 1702/4885POLB 4379/4885 |
| US-10865216-B2 | Tricyclic Gyrase inhibitors | TOP1, TOP2A, TOP2B | PDK1 830/4885MAPK1 2722/4885POLB 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.